Oral topical cyclo-oxygenase 2 inhibitors (COX2-1) mouthwash for the treatment of oral dysplasia

Submission date 23/04/2010	Recruitment status No longer recruiting	Prospectively registered		
		[_] Protocol		
Registration date 23/04/2010	Overall study status Completed	[] Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
29/03/2022	Cancer			

Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-study-using-aspirin-for-pre-cancerous-white-patches-mouth-ASPOD

Contact information

Type(s) Scientific

Contact name Mr Paul Nankivell

Contact details Clifford Bridge Road Coventry United Kingdom CV2 2DX

Additional identifiers

EudraCT/CTIS number 2007-003292-40

IRAS number

ClinicalTrials.gov number NCT01238185

Secondary identifying numbers 6070

Study information

Scientific Title

Oral topical cyclo-oxygenase 2 inhibitors (COX2-1) mouthwash for the treatment of oral dysplasia: a pilot non-randomised interventional proof of concept study

Acronym

ASPOD

Study objectives Pilot study assessing the potential role of aspirin in treating oral dysplasia.

Ethics approval required Old ethics approval format

Ethics approval(s) West Midlands REC approved on the 24th September 2009 (ref: 08/H1208/49)

Study design Non-randomised interventional treatment trial

Primary study design Interventional

Secondary study design Non randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network, Ear; Subtopic: Head and Neck Cancer, Ear (all Subtopics); Disease: Head and Neck, Ear, nose & throat

Interventions

Group 1: Standard dispersible tablets of aspirin 75 mg (BNF) and be instructed to disperse one tablet thoroughly in one glass of 250 ml of water and use as mouthwash for 60 seconds twice a day.

Group 2: Two standard dispersible tablets of aspirin 75 mg (BNF) and will be instructed to dissolve the two tablets thoroughly in one glass of 250 ml of water and use as mouthwash for 60 seconds twice a day.

Group 3: Standard dispersible tablets of aspirin 300 mg (BNF) and be instructed to disperse one tablet thoroughly in one glass of 250 ml of water and use as mouthwash for 60 seconds twice a day.

Group 4: Standard dispersible tablets of aspirin 300 mg (BNF) and be instructed to dissolve the one tablet thoroughly in one glass of 250 ml of water and use as mouthwash for 60 seconds three times a day.

Patients will use the mouthwash for 6 weeks until they return for their second biopsy. Follow up is then whatever is required by the clinical team.

Study entry: registration only

Intervention Type Drug

Phase Not Applicable

Drug/device/biological/vaccine name(s) Aspirin

Primary outcome measure

Level of COX expression, prostaglandin level and change in histological grade measured pre- and post-treatment. Measurement of the primary outcome measures will only occur once all patients have been recruited to the study. Pre and post treatment biopsy samples (6 weeks apart) are snap frozen and stored at -80°C.

Secondary outcome measures

All biochemical measures for the secondary outcomes will be measured at the same time. The histological grade of the tissue will be made within 7 - 10 days of each biopsy being taken as is normal clinical practive for these lesions. The tolerability and side effects will be ascertained on the patients return for their second biopsy (6 weeks after commencing the Aspirin).

Overall study start date 01/02/2010

Completion date 03/10/2011

Eligibility

Key inclusion criteria

- 1. Patients with clinically evident leukoplakia
- 2. Can attend follow up
- 3. Requiring biopsy and surgery
- 4. 18 years old or over, either sex
- 5. Able to give informed consent
- 6. Not known to be pregnant

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned sample size: 40; UK sample size: 40

Total final enrolment

13

Key exclusion criteria

1. Histologically confirmed cancer

2. Prior oral cancer

- 3. Patients on aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid treatment
- 4. Current treatment of oral dysplasia with topical/systemic treatment
- 5. Active peptic ulcer disease
- 6. History of aspirin induced asthma, stomach ulcers or aspirin sensitivity
- 7. History of associated angioedema, urticaria or suspected aspirin allergy in the past

Date of first enrolment

01/02/2010

Date of final enrolment 03/10/2011

Locations

Countries of recruitment England

United Kingdom

Study participating centre Clifford Bridge Road Coventry United Kingdom CV2 2DX

Sponsor information

Organisation Coventry University Hospital (UK)

Sponsor details

Clinical Sciences Research Institute Clinical Sciences Building Clifford Bridge Road Coventry England United Kingdom CV2 2DX

Sponsor type Hospital/treatment centre

Website http://www.uhcw.nhs.uk/

ROR https://ror.org/025821s54

Funder(s)

Funder type Charity

Funder Name Cancer Research UK (CRUK) (UK) (ref: C19677/A8556)

Alternative Name(s) CR_UK, Cancer Research UK - London, CRUK

Funding Body Type Private sector organisation

Funding Body Subtype Other non-profit organizations

Location United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details results	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		25/06/2012		Yes	No
Plain English results		20/11/2013	29/03/2022	No	Yes
HRA research summary			28/06/2023	No	No